Core Viewpoint - Idorsia Ltd. announces the launch of QUVIVIQ® (daridorexant) in China by Simcere Pharmaceuticals, marking a significant advancement in insomnia treatment without psychotropic drug control labeling [1][4]. Group 1: Product Information - QUVIVIQ is a dual orexin receptor antagonist indicated for adult patients with insomnia characterized by difficulty falling asleep and/or maintaining sleep [1]. - Daridorexant selectively blocks orexin neuropeptides, regulating wake signaling, and promotes restorative sleep while reducing morning sleepiness [3]. - Clinical trials showed that 25mg and 50mg doses of daridorexant significantly improved sleep onset, maintenance, and total sleep time compared to placebo [5]. Group 2: Market Context - Insomnia is a major public health challenge in China, with existing treatments often leading to next-day drowsiness and dependence, highlighting the need for safer alternatives [2]. - The launch of QUVIVIQ addresses the unmet need for effective insomnia treatments, positioning it as a meaningful advancement in chronic insomnia management [5]. Group 3: Collaboration and Financials - Idorsia and Simcere entered an exclusive licensing agreement for QUVIVIQ in Greater China, with Idorsia receiving $80 million in milestone payments and eligible for additional payments and royalties on future sales [6]. Group 4: Availability - Daridorexant is commercially available as QUVIVIQ in multiple countries, including the US, Germany, and China, and is approved throughout the EU [7].
Global expansion of Idorsia's QUVIVIQ continues as Simcere launches in China